{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:58:37Z","timestamp":1791464317474,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ygyno.2020.06.479","type":"journal-article","created":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T07:39:28Z","timestamp":1592206768000},"page":"740-746","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach"],"prefix":"10.1016","volume":"158","author":[{"given":"Claudia","family":"Marchetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Minucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"D'Indinosante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Ergasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Arcieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ettore Domenico","family":"Capoluongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Pietragalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Caricato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2020.06.479_bb0005","unstructured":"National Cancer Institute (NIH), Surveillance, Epidemiology and End Results Program: Ovarian cancer section. Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html;"},{"key":"10.1016\/j.ygyno.2020.06.479_bb0010","unstructured":"K.B. Kuchenbaecker, J. L. Hopper, D. R. Barnes et al.\u201cRisks of Breast, Ovarian and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers\u201d. Journal of the American Medical Association-2017;"},{"key":"10.1016\/j.ygyno.2020.06.479_bb0015","doi-asserted-by":"crossref","unstructured":"Moore K, Colombo N, Scambia G, et al: Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379:2495\u20132505;","DOI":"10.1056\/NEJMoa1810858"},{"issue":"9","key":"10.1016\/j.ygyno.2020.06.479_bb0020","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1093\/hmg\/3.9.1679","article-title":"The gene for hereditary breast-ovarian cancer, BRCA1, maps distal to EDH17B2 in chromosome region 17q12-q21","volume":"3","author":"Tonin","year":"1994","journal-title":"Hum. Mol. Genet."},{"issue":"5181","key":"10.1016\/j.ygyno.2020.06.479_bb0025","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1126\/science.8091231","article-title":"Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13","volume":"265","author":"Wooster","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2020.06.479_bb0030","article-title":"Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline","volume":"27","author":"Konstantinopoulos","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2020.06.479_bb0035","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/ng0495-439","article-title":"Somatic mutations in the BRCA1 gene in sporadic ovarian tumours","volume":"9","author":"Merajver","year":"1995","journal-title":"Nat. Genet."},{"issue":"16","key":"10.1016\/j.ygyno.2020.06.479_bb0040","first-page":"3622","article-title":"Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer","volume":"56","author":"Foster","year":"1996","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.ygyno.2020.06.479_bb0045","first-page":"2433","article-title":"Frequency of germline and somatic BRCA1 mutations in ovarian cancer","volume":"4","author":"Berchuck","year":"1998","journal-title":"Clin. Cancer Res."},{"issue":"7353","key":"10.1016\/j.ygyno.2020.06.479_bb0050","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature."},{"issue":"8","key":"10.1016\/j.ygyno.2020.06.479_bb0055","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2020.06.479_bb0060","doi-asserted-by":"crossref","unstructured":"Endris V, Stenzinger A, Pfarr N et al. NGS-based BRCA1\/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial. Virchows Arch. 2016 Jun;468(6):697\u2013705);","DOI":"10.1007\/s00428-016-1919-8"},{"key":"10.1016\/j.ygyno.2020.06.479_bb0065","doi-asserted-by":"crossref","unstructured":"Vos JR, Fakkert IE, de Hullu JA et al. Universal Tumor DNA BRCA1\/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition. JNCI J Natl Cancer Inst (2020) 112(2): djz080;","DOI":"10.1093\/jnci\/djz138"},{"key":"10.1016\/j.ygyno.2020.06.479_bb0070","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/978-3-030-24100-1_2","article-title":"Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer","volume":"1168","author":"Morganti","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ygyno.2020.06.479_bb0075","doi-asserted-by":"crossref","unstructured":"Ferrer I, Armstrong J, Capellari S et al. Effects of formalin fixation, paraffin embedding, and time of storage on DNA preservation in brain tissue: a BrainNet Europe study. Brain Pathol 17(3):297\u2013303. doi:https:\/\/doi.org\/10.1111\/j.1750-3639.2007. 00073;","DOI":"10.1111\/j.1750-3639.2007.00073.x"},{"key":"10.1016\/j.ygyno.2020.06.479_bb0080","doi-asserted-by":"crossref","unstructured":"Callens C, Vaur D, Soubeyran I, et al. BRCA&2 tumoral and germline status for ovarian cancer patients in first line setting within the PAOLA-01 trial. Annals of Oncology (2017) 28 (suppl_5): v330-v354. https:\/\/doi.org\/10.1093\/annonc\/mdx372;","DOI":"10.1093\/annonc\/mdx372.005"},{"issue":"38","key":"10.1016\/j.ygyno.2020.06.479_bb0085","doi-asserted-by":"crossref","first-page":"61845","DOI":"10.18632\/oncotarget.11259","article-title":"Simultaneous detection of BRCA mutations and large genomic rearrangements in germline DNA and FFPE tumor samples","volume":"7","author":"Enyedi","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.ygyno.2020.06.479_bb0090","doi-asserted-by":"crossref","first-page":"152595","DOI":"10.1016\/j.prp.2019.152595","article-title":"BRCA1\/2 somatic mutation detection in formalin-fixed paraffin embedded tissue by next-generation sequencing in Korean ovarian cancer patients","volume":"215","author":"Lee","year":"2019","journal-title":"Pathol. Res. Pract."},{"issue":"2","key":"10.1016\/j.ygyno.2020.06.479_bb0095","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.18632\/oncotarget.6834","article-title":"BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing","volume":"7","author":"Mafficini","year":"2016","journal-title":"Oncotarget."},{"issue":"1","key":"10.1016\/j.ygyno.2020.06.479_bb0100","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ygyno.2015.07.095","article-title":"Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: proof of a concept","volume":"139","author":"Petrillo","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.479_bb0105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ygyno.2010.09.010","article-title":"Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment","volume":"120","author":"Aletti","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.479_bb0110","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41439-018-0006-x","article-title":"High-resolution melting analysis coupled with next-generation sequencing as a simple tool for the identification of a novel somatic BRCA2 variant: a case report","volume":"5","author":"Costella","year":"2018","journal-title":"Hum Genome Var."},{"key":"10.1016\/j.ygyno.2020.06.479_bb0115","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.cca.2018.02.012","article-title":"A comprehensive BRCA1\/2 NGS pipeline for an immediate Copy Number Variation (CNV) detection in breast and ovarian cancer molecular diagnosis","volume":"480","author":"Concolino","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ygyno.2020.06.479_bb0120","doi-asserted-by":"crossref","unstructured":"Minucci A, Mazzuccato G, Marchetti C. et al: Detecting germline rearrangements of BRCA1 by next generation tumor sequencing. Mol. Biol. in press (2020);","DOI":"10.1134\/S0026893320030127"},{"key":"10.1016\/j.ygyno.2020.06.479_bb0125","first-page":"A7","article-title":"11 Flabra, frontline approach for BRCA testing in ovarian cancer (OC) treatment na\u00efve population","volume":"29","author":"Goncalves","year":"2019","journal-title":"A Latin America (LA) Epidemiologic Study International Journal of Gynecologic Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2020.06.479_bb0130","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.ygyno.2020.06.479_bb0135","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observation","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.ygyno.2020.06.479_bb0140","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer. Chem. Rep."},{"issue":"12","key":"10.1016\/j.ygyno.2020.06.479_bb0145","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1245\/s10434-018-6700-6","article-title":"BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study","volume":"25","author":"Marchetti","year":"2018","journal-title":"Ann. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2020.06.479_bb0150","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/sj.ejhg.5200755","article-title":"BRCA mutations in Italian breast\/ovarian cancer families","volume":"10","author":"Nedelcu","year":"2002","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ygyno.2020.06.479_bb0155","doi-asserted-by":"crossref","unstructured":"Ray-Coquard IL, Pautier P, Pignata S, et al: Phase III PAOLA-1\/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Ann Oncol 30, 2019 (suppl 5; abstr LBA2_PR);","DOI":"10.1093\/annonc\/mdz394.053"},{"key":"10.1016\/j.ygyno.2020.06.479_bb0160","unstructured":"Gonzalez-Mart\u0131n A, Pothuri B, Vergote I et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa1910962;"},{"issue":"49","key":"10.1016\/j.ygyno.2020.06.479_bb0165","doi-asserted-by":"crossref","first-page":"81357","DOI":"10.18632\/oncotarget.12877","article-title":"Performance of multiplicom\u2019s BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples","volume":"7","author":"Badoer","year":"2016","journal-title":"Oncotarget."},{"key":"10.1016\/j.ygyno.2020.06.479_bb0170","doi-asserted-by":"crossref","unstructured":"Petrillo M, Marchetti C, De Leo R et al. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. Am J Obstet Gynecol. 2017 Sep;217(3): 334.e1\u2013334.e9.","DOI":"10.1016\/j.ajog.2017.05.036"},{"key":"10.1016\/j.ygyno.2020.06.479_bb0175","doi-asserted-by":"crossref","unstructured":"Kwon JS, Tinker AV, TA, Karsanc A, et al: Costs and benefits of tumor testing for BRCA mutations in high-grade serous ovarian cancer as a companion diagnostic for PARP inhibitor treatment. Presented at the Society of Gynecologic Oncology's 50th Annual Meeting on Women's Cancer, Honolulu, HI, March 16\u201319, 2019.","DOI":"10.1016\/j.ygyno.2019.04.411"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820322940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820322940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:51:02Z","timestamp":1758772262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820322940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0090825820322940"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.06.479","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.06.479","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}